GSK plc 通知伦敦证券交易所新增 19,352 股普通股获准交易
6-K - GSK plc (0001131399) (Filer)
GSK plc 披露，19,352 股每股面值 31¼ 便士的普通股已在伦敦证券交易所主板获准交易，相关通知覆盖 8 月 7 日至 10 月 2 日。此次股份纳入现有的 GSK Share Save Plan 2022 区块上市安排，获准交易后普通股总数为 4,316,311,662 股。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 6 October 2026, London UK
Admission to trading
In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each (‘Ordinary Shares’) have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the “GlaxoSmithKline plc Share Save Plan 2022”.
|
1a |
Issuer name |
GSK plc |
|
1b |
Issuer LEI |
5493000HZTVUYLO1D793 |
|
2 |
Regulated market on which the securities have been admitted to trading |
London Stock Exchange – Main Market |
|
3 |
Name, type and ISIN of the securities |
Ordinary Shares of 31¼ pence each ISIN: GB00BN7SWP63 |
|
4 |
Number of further securities admitted to trading covered by this notification |
19,352 |
|
5 |
Total number of securities admitted to trading following admission |
4,316,311,662 |
|
6 |
Fungibility |
Fully fungible with existing Ordinary Shares |
|
7 |
Date range covered by the notification |
7 August 2026 – 2 October 2026 |
|
8 |
Prospectus information |
N/A |
V A Whyte
Company Secretary
6 October 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
|
GSK plc |
|
|
(Registrant) |
|
|
Date: October 06, 2026 |
|
|
By:/s/ VICTORIA WHYTE -------------------------- |
|
|
Victoria Whyte |
|
|
Authorised Signatory for and on |
|
|
behalf of GSK plc |
来源：SEC EDGAR · 本站存档